Good day, everyone, and welcome to today's Astrana Health First Quarter 2024 Earnings Call. [Operator Instructions] Today's speakers will be Brandon Sim, President and Chief Executive Officer of Astrana Health; and Chan Basho, Chief Operating and Financial Officer. The press release announcing Astrana Health Inc.'s results for the first quarter ended March 31, 2024, and available at the Investors section of the company's website at www.astranahealth.com. The company will discuss certain non-GAAP measures during this call. Reconciliations to the most comparable GAAP measures are included in the press release. To provide some additional background on its results, the company has made a supplemental deck available on its website. A replay of this broadcast will also be made available at Astrana Health website after the conclusion of this call. Before we get started, I would like to remind everyone that this conference call and any accompanying information discussed herein contains certain forward-looking statements within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terms such as anticipate, believe, expect, future, plan, outlook and will and include, among other things, statements regarding the company's guidance for the year ending December 31, 2024, continued growth, acquisition strategy, ability to deliver sustainable long-term value, ability to respond to the changing environment, operational focus, strategic growth plans and merger integration efforts. Although the company believes that the expectations reflected in its forward-looking statements are reasonable as of today, those statements are subject to risks and uncertainties that could cause the actual results to differ dramatically from those projected. There can be no assurance that those expectations will prove to be correct. Information about the risks associated with investing in Astrana Health is included in its filings with the Securities and Exchange Commission, which we encourage you to review before making an investment decision. The company does not assume any obligation to update any forward-looking statements as a result of new information, future events, changes in market conditions or otherwise, except as required by law. Regarding the disclaimer language, I would also like to refer you to Slide 2 of the conference call presentation for further information. With that, I'll turn the call over to Astrana Health's President and Chief Executive Officer, Brandon Sim. Please go ahead, Brandon.

Thank you, operator. Good evening, and thank you all for joining us today. We began 2024 with a strong first quarter here at Astrana Health as we expand our innovative care model and technology platform to empower entrepreneurial providers and improve health care in local communities throughout the country. We continue to deliver against our strategic road map and are proud to announce compelling financial, operational and clinical results to start the year. I'll start by highlighting our financial performance for the first quarter of 2024. Total revenue at Astrana reached $404 million, a 20% increase compared to the prior year period, and adjusted EBITDA rose to $42.2 million, up 42% compared to the prior year period. This resulted in an adjusted EBITDA margin of 10.4%. Both growth and profitability metrics were driven by robust membership growth across all our lines of business, coupled with ongoing success in managing the total cost of care for these members and value-based risk-bearing arrangements. We also continued investing in our teams, our technology platform and our new market entry operations. We believe these investments are critical towards our ongoing commitment to building a sustainable business even as we continue to expand rapidly. As a reminder, we have consistently talked about the 4 pillars of our business, which we feel our platform is uniquely positioned to execute on: one, expanding our membership base across existing and new geographies; two, increasing the level of accountability and risk we are responsible for our value-based care contracts; three, empowering our providers to achieve superior patient outcomes; and four, executing strategic acquisitions to further accelerate our growth trajectory. On the first pillar, we experienced robust growth at membership in both core and new regions. We now manage approximately 1 million lives driven by robust organic growth and strategic…

Thank you, Brandon. Moving into this quarter's performance. We began 2024 with total revenue of $404 million, a 20% increase from $337 million in the prior year quarter. This was primarily driven by increased capitation revenue, resulting from organic membership growth in our core IPAs as well as the addition of CFC IPA on January 31, 2024. Care Partners revenue increased 26% to $397 million during the period. Along with the organic and strategic growth, Partners revenue increased due to the conversion and addition of full-risk membership. As of April 1, 2024, we expect our full-risk business to account for approximately 60% of capitated revenues relative to 49% as of January 1, 2024. Adjusted EBITDA was $42.2 million, up 42% from $29.8 million in the prior year period. In the first quarter of 2024, adjusted EBITDA excluded certain onetime items, including a $4.7 million expense related to a financial guarantee via a letter of credit that we provided 2 years ago in support of 2 independently operated local provider-led ACOs. Despite the removal of these ACOs from the CMS program, the shared losses for that year were recorded, and we are working with those 2 providers to recoup the funds that were spent. As I mentioned, this is not a recurring item nor do we believe it reflects the operations of our ACO business. Net income attributable to Astrana Health was $14.8 million, an increase of 13% from $13.1 million in the prior year quarter. Earnings per share on a diluted basis were $0.31, up 11% from $0.28 in the prior year. Now turning to the balance sheet. Our financial position remains well capitalized with $335 million in cash and cash equivalents and total debt of $393 million as of Q1 2024. This compares to $294 million in cash and…

Ladies and gentlemen, the floor is now open for questions. [Operator Instructions] And we'll take our first question from Ryan Daniels from William Blair.

I'm curious if you could speak a little bit more to your pipeline, either for new partnerships or M&A, especially as we contrast your strong performance versus what some other peers are seeing in the market? Meaning, is that opening up some opportunities? Is there pressure with provider groups to get new partnerships, et cetera? Just any color there would be great.

Ryan, thank you so much for the questions and for tuning in. I think we're seeing a very strong partnership and corporate development pipeline as we speak. As you mentioned, there is a huge desire, especially given cost pressures, margin pressures, utilization trends that some of our peers are seeing to find a partner that is going to be stable and present a long-term opportunity to provide value back to providers and ultimately back to the patients. And so I think we're absolutely seeing a strong pipeline. I think there was an acquisition that we announced during our Care Partners segment this quarter and the close of the CFC transaction. And I believe we are still planning to fulfill our guidance of at least 1 or 2 new markets per year as the year progresses here.

Okay. That's helpful color. And then as my follow-up, good new data on the total cap revenue being at 60%, up from 49% in January. I guess my question is now that you have both the Medicare and Medicaid RKK how might we see that trend kind of towards year-end? So where might you end the year in 2024? And then what would your goals be for 25 and 26 because I know that's a nice kind of revenue and really a care management accelerator as well. And congrats on the strong performance.

Thanks, Ryan. In terms of our year-end target, as we've discussed before, we still expect to be at about 2/3 by year-end in our transition to full risk. As we work through 2025. We see us continuing to move our membership into a full risk arrangement, and we do believe we will be able to get the majority of our contracts into full risk by the end of 2025.

Thank you. And we'll take our next question from David Larsen from BTIG.

Congratulations on the quarter. I was positively surprised at the EBITDA. Can you maybe just talk about claims trend, how that's tracking for your book of business? Some of your peers were hearing sustained high MA utilization, fairly high single-digit claims cost trend. I mean what are you seeing? How did your caution come in relative to your own expectations? And I guess, what is your secret sauce? Why is your trend perhaps better than others?

David, great to hear from you. Thanks so much for the -- thanks so much for the question. In terms of how we're looking at utilization, first, in terms of flu, we saw an equivalent to maybe a higher amount of flu cases but a lower level of acuity. In terms of overall claims trend, as you know, because we do have full visibility around our utilization, management and care management capabilities, which leads to us having visibility around authorizations. We are able to have a clearer sense of around MCR. And we see across the board positive trends there, as Brandon mentioned during the call. We see some areas where, for example, due to regulatory reasons, genetic testing is now included in certain Medicaid-related cases. So we see an increase there. No real -- but beyond that, we continue to see MCRs that are consistent or favorable relative to historical periods.

Okay. And then can you put a percent number on your perimeter per month trend line? Is it below 5%? Is it between 5% and 10%, below 3%? Any number you can put on that?

Dave, thanks for the question. This is Brandon. I don't think we've disclosed the exact trend line, especially because it differs by line of business. I would say that across all lines of business, Medicare, commercial and MA, I would say it's coming in a few percent lower than we had anticipated at the beginning of the year prior to this year, prior to this quarter. It is still early in the year, I would say. So we're here in May, and we had a conservatism reaffirmed guidance, but I do think early results, starting off the year here are promising.

Okay. And then can you maybe talk a little bit about your approach to managing inpatient services? I mean, it's my understanding that you actually have Astrana hospitalists that managed care to an extent within inpatient facilities. So should we be worried about a spike in claims cost for hospitals once you start sort of bearing more full risk?

There definitely will be higher claims costs obviously offset by higher claims, higher capitation revenue as we continue to move into full risk we're starting to see that already as we get to around 60% of our capitated revenue in full risk arrangements. However, we don't -- while that may be a temporary pressure to overall EBITDA margin as we've formally discussed, from a raw EBITDA number perspective, it's still accretive, certainly, and we think we're well prepared to take on the full risk and maintain medical margins where we would like them to be because of the ability we have in terms of our hospitals working at the hospitals in terms of our post-discharge care teams taking care of folks after inpatient visits and in terms of our deep specialist and primary care provider integration for patients across the care continuum spectrum? Even as we grow into new markets, we're seeing -- we're able to contract effectively with hospitals and replicate some of the elements that we've used in California to successfully manage cost of care in both outpatient and inpatient settings. So that's something we continue to keep in mind. For example, as we enter full risk delegated contracts here in Nevada or in Texas or beyond.

Okay. That's great. Very helpful. And then just last one, like CFC integration, how is that progressing? Just any thoughts or color there would be very helpful.

Sure thing. Yes. The CFC integration, as I mentioned in the prepared comments are -- is going very well. We've -- all the providers are now are already on our Care Enablement platform. Obviously, given that it powered CFC even prior to acquisitions from a regulatory standpoint, things have been settled, leading to the successful close on March 31, and the second part of the CFC transaction and throughout the remainder of the year, most of the CFC members already in forward contracts dating back to the middle of 2023, and there are additional synergies with our existing business that we look to capitalize on for the remainder of the year.

Okay. Congratulations on a great quarter. I'll hop back in the queue.

Thank you so much, Dave.

And we'll take our next question from Adam Ron from Bank of America.

Super quick ones. So the 60% number that you're talking about for capitation that you're using, I want to make sure I understand it. So you're saying for 60% of what you're reporting as capitation revenue, that number that you're reporting is some capitation rate, let's call it, 85% of whatever the benchmark that you're managing is. And if that's true, that I'm understanding that correctly, on the remaining 40%, what is roughly the capitation rate that you're doing today? And can that go to 85% to that could give us like a sense of like what the dollar opportunity in revenue is from here.

Question. You're absolutely correct in your understanding, 60% of the capitated revenue that we report in the Care Partners segment comes from an arrangement in which call it, yes, approximately 85% of the premium dollar is being given to us in a capitated value-based arrangement. Of the other 40% of the dollars, I would say that those are mostly coming from arrangements in which we have outpatient risk only, which would be illustratively, call it, around 35% to 40% of the premium dollar. So there is additional opportunity we anticipate capturing some of it over the remainder of this year, some of it into 2025 in terms of converting some of those contracts into 4 is 85-approximately percent of premium contracts.

Okay. No, that's perfect. And then in terms of MLR, it seems pretty significant to your point, a trend was a couple of percentage lower than what you thought it was, which on a 10% margin business is pretty substantial. So, yes. Just curious, one, why you didn't raise the guidance? And two, what are the big factors versus expectations that are coming in different. And three, somewhat unrelated, but in the 2025 rate notice, one of the surprising aspects was in Los Angeles, the rate for growth rate of trend was 5%, while the rest of the industry got like 2.4% or something. So curious, it's like CMS' view of what's happening in L.A. County is different from yours, where potentially they're saying trend is accelerating? And then on the other hand, into '25, is that a tailwind for you? Or is it entirely offset by what the payers are doing with benefits. I appreciate the answer to the multifacet question. In advance.

Yes, correct. I'll try to take them one out of time, Adam. So on the -- Well, I just want to clarify in my prior response to the 60% of capitated revenue that's for risk is as of April 1, just the day after the end of the quarter here. after the close of the just taking that clear. In terms of kind of the utilization trends that we're seeing, as Chan mentioned and I talked about, I'll give a little more color. We are encouraged, cautiously optimistic about the trends we're seeing in terms of utilization. We are seeing kind of broad-based support for the increase -- or the decrease is rather a utilization trend across different lines of business, different pockets of the business. There are a couple of pockets that Chan mentioned earlier, for example, that are maybe higher than expected, but overall, the trend is very positive. I would say that the reason for not increasing guidance at this point in time, it's still early in the year, Adam, I think we, again, cautiously optimistic, but I think we probably still fall within the range. There is increased -- there's a bit of increased investment in the teams in new market entry. And we think we're on track, and we'll provide more updates as the year progresses. In terms of the question on Los Angeles [indiscernible] benchmarks. Overall, I would say we were fairly disappointed as others were with the MA rate notice, the final notice. I think the -- as you mentioned, the LA benchmark came in a little higher than maybe we had thought or compared to other regions. So we think that could be a tailwind for sure. But that's -- again, it's still early in the year. We're still negotiating and talking to payers, working with our partners around some of the benefits that will take place in '25, how the plan will be designed. So all of this will holistically probably be -- will go into the final kind of economics that we anticipate for coming by. So we'll have further guidance on that to you in the coming months.

[Operator Instructions] We will take our next question from Jack Slevin from Jefferies.

Congrats on the quarter. I wanted to do a bit of a double click on the Nevada contract. Can you give a little more color on maybe what payer class that risk contract represents? And sort of what you're seeing that made you want to flip that on immediately in Nevada is sort of the infrastructure and the market entry costs you've been building up over the last year are there and ready to hit the ground running on it?

Jack, Yes. So in Nevada, we've been in some shared risk arrangements or partial risk arrangements for about a year, maybe a little more than a year at this point. Before risk contract that we turned on was the Medicare Advantage contract? And it's one in which we actually have delegated payer responsibilities. So we have utilization management, care management, claims, credentialing contracting, et cetera, which very much looks similar to the infrastructure we built in California. We felt comfortable turning it on after looking at some of the results while participating under a shared risk arrangement as well as the confidence in the infrastructure we've now built in Nevada over the last, call it, 12 to 18 months. So it's something that, while still a fairly small book of business, relatively speaking, we're excited to continue to prove the model scales outside of some of our core regions.

Got it. And then just on the full risk transition, a lot of moving pieces that we're hearing from MA plans in particular, but sort of on cost trend broadly. Just thinking about -- I know you guys have a lot of visibility into the opportunity there given the role that you play currently. But as you think about adding inpatient risk, throughout a lot of probably what is the California base? How are you measuring up sort of moving pieces with cost trends that are underlying and move that plans might be making on how they bid into next year when factoring in how you do transition those lives? Is it sort of still just push on as quickly as you can? Or do you have to be a little more selective given the environment?

Yes. No, Sorry, Chan, go ahead.

No, no. So, Jack, in terms of our contracts, I don't want you to think we're moving contracts over if actuarially post analysis, it doesn't make sense for us to do so. So we are looking at our claims trend. We are looking at overall medical trend. We are looking at the unique capabilities we can bring to that market in terms of our medical management capabilities, our care management capabilities and the technology that we can offer in that local marketplace. And as that links together and in many markets, we have amount of risk already. We then move forward in a very prudent fashion.

Got it. Appreciate the color. And congrats again on really strong quarter.

And next, we will go to Jailendra Singh from Truist.

First question on the care delivery business, saw around $8 million sequential decline. I understand last quarter, in Q4, you had some true-ups, so that probably was expected. But anything you can highlight there in terms of trends you saw in the business? And is Q1 the good run rate for rest of the year for that business? Just trying to understand if there was any impact from change health care disruption on that business?

Jailendra, thanks so much for your question. In terms of the change from Q4 to Q1, Q4 and Q2 is usually when there's annual quality bonuses as well as any onetime true-ups that happened on the delivery side of the business. So that's the change that you see. In terms of change and the impact, we have very minimal change related business in terms of our delivery assets so that there's not an impact there.

Okay. use Q1 as a good run rate for the rest of the year, right, from a revenue point of view.

Yes, we will see some enhanced profitability in Q2 and Q4 from those bonuses as they come in.

Right. Then my follow-up, a managed care company, I mean, player last we called out pressure in the ACO business driven by some data they received by -- from CMS impacting their '23 reserves and also their 2024 assumptions. With you guys entering MSSP this year, and I believe you are accruing towards breakeven margins. Just curious what you have seen in data, I understand it's clearly limited, but just curious if for anything to flag from your experience point of view. And similarly, outside of the $4.7 million adjustment you called out in ACO reach, can you talk about your experience in that program in general?

Jailendra, thank you for the question. I think your question -- first question, and please correct me if I'm wrong, is around MSSP and our experience so far is early on. And we had undergo approximately breakeven given the first year of our participation. In MSSP, we are still underwriting this quarter to a breakeven, given the lack of large experience in that program? I would probably guess that MSSP profitability, especially because it's coming in on a 15- to 18-month cycle would probably show up most likely in 2025 financials and not this year, and we haven't contemplated any profitability from [indiscernible] ACO in this year's financial projections. On the ACO reach business, which we do have more experience in a couple of clarifying points. The first is that the $5 million adjustment that Chan mentioned, that was fully taken in terms of the charge this quarter. It's a onetime thing, but also isn't related to our ACO reach, but rather separate ACO reach businesses as China explained earlier. In terms of our ACO reaches performance, we're actually seeing pretty promising results. We are booking a bit of profitability this quarter, as Chan mentioned, because of the increased visibility and the confidence we have that the medical cost trends are fairly positive even in the ACO reach program.

[Operator Instructions] We'll go to Christian Borgmeyer from TD Securities.

This is Christian Borgmeyer on to Gary Taylor. So as we think about the Medicaid retermination period winding down, what are you seeing lately in terms of reenrollment through exchange and commercial products? Are you noting any disruptions in care for patients as they navigated through any reenrollment. And if there's been a lapse and care, what tools is a strong to deploy to reengage the members that may have not been seeing their PCPs lately.

Christian, thank you for the question. As I mentioned earlier, we still saw growth in Medicaid around 7% year-to-date, even net redetermination in the commercial class exchange business rose by even more than that. It was well over 16%, I believe, in the commercial segment based on some of the recaptures I mentioned, of coming the Medicaid members into stages. I would say that the efforts have largely gone successfully. Medicaid as a business has still grown despite determination, and we're not seeing any higher activity levels in the remaining Medicaid members as compared to prior to return -- redetermination. And as you mentioned, the redetermination period is ending in a sort of while. So I think -- for the most part, headwinds around that redetermination program are generally mitigated from our point of view. In terms of member engagement, continuity of care, we think that's really a strong point of differentiation for our model. Patients will be determined or in a different type of insurance plan or even a different payer. I know it's not your question, but even for Medicare Advantage. So have access to the exact same care teams, social workers, [indiscernible] planning, technology platform and primary and [indiscernible] care providers and now increasingly, 60% of it for their institutional network as well. And so there's really a strong ability for us to continue care in the exact same way the patient has experienced it, leading to more longitudinal relationship with the patient and ultimately investing -- allowing us to invest more in the patient's health over time. So we think that's a big part of the model I discussed earlier is that we are so diverse in terms of how we serve the patient, and we think that's paying off as we've gone through this Medicaid lease termination process.

[Operator Instructions] And there appear to be no further questions at this time. I'd like to turn the floor back to Brandon Sim for closing remarks.

Thank you, everyone, for tuning in this evening to our first quarter 2024 earnings results. As always, we are around in our offices in both Alhambra, California and Las Vegas, Nevada. If you're in the area, please don't hesitate to e-mail us if you'd like to meet. We look forward to discussing our results next quarter and see you again. Thank you, and have a good evening.

Thank you. Ladies and gentlemen, this does conclude today's teleconference. We thank you for your participation. You may disconnect your lines at this time, and have a great day.